Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Phase II Study of Compliance and Morbidity with 4 Cycles of Taxotere Followed by 4 of Doxorubicin-Cyclophosphamide for Adjuvant Treatment of Operable Breast Cancer Patients

  • Yaghan, Rami Jalal (Faculty of Medicine, Jordan University of Science and Technology and affiliated King Abdulla Teaching Hospital) ;
  • Dagher, Nawaf Mahmood (Faculty of Medicine, Jordan University of Science and Technology and affiliated King Abdulla Teaching Hospital)
  • Published : 2016.08.01
⟨ Previous Next ⟩

Abstract

Background: In the adjuvant treatment of breast cancer, anthracycline and taxane based regimens can be used concomitantly or sequentially. The best order in the sequential regimens has yet to be well established. This study evaluated the feasibility of 4 cycles of adjuvant taxotere ($100mg/m^2$) every 3 weeks followed by 4 cycles of doxorubicin ($60mg/m^2$) and cyclophosphamide ($600mg/m^2$) every 3 weeks. The primary outcome was the safety profile. Secondary outcomes were disease free survival (DFS) and overall survival (OS). Materials and Methods: This non-randomize prospective phase II stud was performed at Jordan University of Science and Technology and its affiliated King Abdulla Teaching Hospital between July 2009 and August 2010. Data collection was closed on May $31^{th}$, 2015 giving a median follow up period of 62 months. The study was approved by the institutional review board and a written informed consent was obtained for each patient. Results: Fifty patients were enrolled. The median age was 53.1 years (range 34-76). One patient (2%) had stage I disease, 17 (34%) stage II, and 32 (64.0%) stage III. Forty-six patients were evaluable for efficacy analysis. The completion rate was 95.7%. No dose modifications were needed. The incidences of grade 3-4 neutropenia and febrile neutropenia were 14 % and 10%. No grade 3-4 non-hematological adverse events were encountered. At a median follow up time of 62 months the OS and the DFS rates were 76.1% and 56.5%. Those for stages I and II combined were 100% and 75%. Conclusions: Taxotere first followed by doxorubicin-cyclophosphamide appears a feasible regimen as evidenced by an acceptable completion rate, a satisfactory safety profile, and an OS and DFS rates comparable to other studies.

Keywords

References

  1. Abe H, Mori T, Kawai Y, et al (2013). Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer. Int J Clin Oncol, 18, 487-91. https://doi.org/10.1007/s10147-012-0407-7
  2. Al-Muqbel KM, Yaghan RJ (2013). Value of baseline and followup whole-body bone scans in detecting bone metastasis in high-risk breast cancer patients. Nucl Med Commun, 34, 577-81. https://doi.org/10.1097/MNM.0b013e328360d6d5
  3. De Laurentiis M, Cancello G, D'Agostino D, et al (2008). Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol, 26, 44-53. https://doi.org/10.1200/JCO.2007.11.3787
  4. Denduluri N, Somerfield MR, Eisen A, et al (2016). Selection of optimal adjuvant chemotherapy regimens for Human Epidermal Growth Factor Receptor 2 (HER2)-negative and adjuvant targeted therapy for HER2-positive breast cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline. J Clin Oncol, 34, 2416-27. https://doi.org/10.1200/JCO.2016.67.0182
  5. Early Breast Cancer Trialists’ Collaborative Group (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet, 365, 1687-717. https://doi.org/10.1016/S0140-6736(05)66544-0
  6. Francis P, Crown J, Di Leo A, et al (2008). Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst, 100, 121-33. https://doi.org/10.1093/jnci/djm287
  7. Kim SB, Sayeed A, Villalon AH, et al (2016). Safety Analysis of adjuvant chemotherapy with docetaxel administered with or without anthracyclines to early stage breast cancer patients: combined results from the Asia- Pacific Breast Initiatives I and II. Asian Pac J Cancer Prev, 17, 697-702. https://doi.org/10.7314/APJCP.2016.17.2.697
  8. Piedbois P, Serin D, Priou F, et al (2007). Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Ann Oncol, 18, 52-7. https://doi.org/10.1093/annonc/mdm036
  9. Polyzos A, Malamos N, Boukovinas I, et al (2010). FEC versus sequential docetaxel followed by epirubicin/ cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Res Treat, 119, 95-104. https://doi.org/10.1007/s10549-009-0468-0
  10. Puhalla S, Mrozek E, Young D, et al (2008). Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary nodepositive breast cancer. J Clin Oncol, 26, 1691-7. https://doi.org/10.1200/JCO.2007.14.3941
  11. Reinisch M, von Minckwitz G, Harbeck N, et al (2013). Side effects of standard adjuvant and neoadjuvant chemotherapy regimens according to age groups in primary breast cancer. Breast Care, 8, 60-6. https://doi.org/10.1159/000346834
  12. Roche H, Fumoleau P, Spielmann M, et al (2006). Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol, 24, 5664-71. https://doi.org/10.1200/JCO.2006.07.3916
  13. Spielmann M, Tubiana-Hulin M, Namer M, et al (2002). Sequential or alternating administration of docetaxel (Taxotere) combined with FEC in metastatic breast cancer: a randomised phase II trial. Br J Cancer, 86, 692-7. https://doi.org/10.1038/sj.bjc.6600165
  14. Thiery-Vuillemin A, Llombart-Cussac A, Chaigneau L, et al (2011). Sequential taxane and anthracycline-containing neoadjuvant regimens: the sequential order impact. Breast, 20, 46-9. https://doi.org/10.1016/j.breast.2010.07.001